# HYDROSPACE (NCT06451614)

> SpaceIT Hydrogel System for Perirectal Spacing

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06451614
- Phase: NA
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Boston Scientific Corporation
- Conditions: Prostate Cancer
- Interventions: SpaceIT Hydrogel System; Commercially available Boston Scientific Spacer
- Enrollment: 230
- Primary outcome: Primary Safety Endpoint - Acute Grade 3 or greater adverse events.
- Primary outcome: Primary Effectiveness Endpoint - 25% reduction in the volume of the rectum receiving 90% of the prescribed radiation dose

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=hydrospace-nct06451614